Regarding long-term studies, Eli Lilly's package insert for Zyprexa 8 disclosed that, during treatment lasting a median of 238 days, 56% of patients gained more than 7% of their baseline weight, with an average weight gain of 5.4 kg. Haberfellner and Rittmannsberger 9 found that 67% of olanzapine-treated patients gained more than 7% of baseline initial body weight with a mean weight gain of 7.7 kg during the first year of treatment. In a 3-year, retrospective chart review, 86% of patients on olanzapine treatment gained an average of 3.65 kg. 10 Four studies comparing olanzapine with other atypical antipsychotics found olanzapine was significantly associated with a greater weight gain. 6, [11] [12] [13] A retrospective analysis of children and adolescents receiving olanzapine or quetiapine found that patients taking olanzapine had significantly increased weight and body mass index (BMI) compared with other patients taking quetiapine. 6 A long-term study 11 comparing olanzapine and risperidone found a statistically significant (p < .005) difference in weight gain between these atypical antipsychotics (8.34 vs. 2.74 kg). A 6-month, open, observational study 12 comparing olanzapine and risperidone found significant weight gains in both groups, with 11.3 kg of weight gain in the olanzapinetreated group (p = .001) and 5.9 kg in the risperidone group (p = .023). Another long-term study 13 of risperidone and olanzapine found a greater rate of weight gain in olanzapine-treated patients (57%) than risperidone-treated patients (13%). In another study, 14 olanzapine-treated patients who had gained more than 20% in weight lost an average of 2.25 kg (p = .03) 10 weeks after being switched to quetiapine. However, merely discontinuing olanzapine may counteract any weight gain; an animal study found that body weight returned to baseline levels once olanzapine was discontinued. 5 This study also compared olanzapine with haloperidol and found that haloperidol was not associated with increased weight or food consumption.
Another reason olanzapine may not be a preferred treatment for anorexia nervosa is that patients with anorexia nervosa are especially vulnerable to weight gain from olanzapine. Two studies found that having a lower BMI is associated with very significant weight gain. 9, 11 In their discussion, Barbarich and colleagues 1 de-emphasized their small sample size and the high dropout rate in their study. Readers could therefore misconstrue the validity of the results. Moreover, the "major limitation" of the study should be its brief duration of 6 weeks. Anorexia nervosa is a chronic disease that requires long-term treatment. However, long-term use of olanzapine is associated with increasing risk of patient weight gain. [8] [9] [10] [11] [12] Because patients with anorexia nervosa have a morbid fear of weight gain and obesity, long-term compliance with olanzapine treatment would be problematic for them.
The authors also asserted, "Currently, there are no other effective pharmacotherapies that significantly improve behavior in ill patients with anorexia nervosa." 1(p1482) The literature and one of the authors himself do not support this statement. Kaye and colleagues 15 found that approximately two thirds of individuals with eating disorders had at least 1 anxiety disorder during their lifetimes, with obsessive-compulsive disorder and social phobia being most common. Moreover, patients with eating disorders in remission without prior anxiety disorders had tendencies toward anxiety, perfectionism, and harm avoidance. Anxiety disorders and tendencies toward anxiety disorders make the selective serotonin reuptake inhibitors reasonable candidates for patients with anorexia nervosa.
Indeed, a MEDLINE literature search 16 from 1966 through 2003 found that fluoxetine helped reduce symptoms of obsessive-compulsive disorder and depression in patients with anorexia nervosa; the author of the review recommended that fluoxetine be used for relapse prevention or to treat anorexia nervosa symptoms after weight restoration.
One of this study's authors (Kaye) has previously published 2 articles about the efficacy of fluoxetine in treating anorexia nervosa. Kaye and colleagues 17 reported a long-term, open trial in which fluoxetine helped 29 of 31 anorexia nervosa patients maintain their body weight at or above 85% average body weight. Kaye and colleagues 18 also reported a double-blind, placebo-controlled study of fluoxetine treatment of 35 patients with the restricting type of anorexia nervosa. Sixty-three percent of these patients remained on fluoxetine treatment for 1 year and had reduced relapse rates. Another study 19 reported improved symptoms of depression and weight gain in anorexia nervosa patients treated with fluoxetine. Yet another study 20 found that monotherapy with venlafaxine or fluoxetine increased BMI and reduced scores on the Eating Disorder Examination. Moreover, only venlafaxine reduced State-Trait Anxiety Inventory scores.
Three studies support the efficacy of citalopram in treating anorexia. Fassino 22 Finally, a 6-month, open trial of low-dose haloperidol found it effective as an adjunctive treatment in reducing Eating Disorder Inventory score, Clinical Global Impressions-Improvement scale score, Eating Disorder Inventory total score, and the Eating Disorder Inventory subscales of drive for thinness, bulimia, and interoceptive awareness scores. 23 In conclusion, the potential benefits of olanzapine use in anorexia nervosa must be weighed with its limitations (especially weight gain) and alternative medications that show efficacy.
Dr. Menaster reports no financial affiliation or other relationship relevant to the subject matter of this letter.

Michael Menaster, M.D.
Private Practice San Francisco, California
Ms. Barbarich-Marsteller and Dr. Kaye Reply
Sir: In response to the letter to the editor "Use of Olanzapine in Anorexia Nervosa," we would like to address the author's criticisms. We appreciate the author's concerns and interest in improving treatment for anorexia nervosa.
It is well known that individuals with anorexia nervosa are inherently difficult to treat, even in an inpatient setting. Moreover, it has been argued 1 that inpatients with anorexia nervosa are more than twice as likely (33.3%) 1 to drop out of an inpatient treatment program than individuals in a general psychiatric ward (16%). 2 In our study, there were 3 subjects who left the treatment program against medical advice. The author of the letter states, "It is reasonable to conclude that weight gain resulting from olanzapine treatment was a factor." However, there were no significant differences in mean weight gain between the 12 subjects who completed the full 6 weeks of the study (7.0 ± 2.0 kg) and either the 3 subjects who left against medical advice (7.4 ± 1.2 kg, p = .74) or the 5 subjects who completed less than 5 weeks of the study (5.6 ± 3.0 kg, p = .29). Therefore, the evidence does not support the author's conclusion that weight gain resulting from olanzapine use was a factor in terminating treatment. Moreover, one rationale for using an atypical antipsychotic such as olanzapine in the treatment of anorexia nervosa is to promote weight gain in order to attain the stable weight and nutritional status needed for psychological treatments to be effective.
In our article, we argued that "currently, there are no other effective pharmacotherapies that significantly improve behavior in ill patients with anorexia nervosa." Dr. Menaster's response that "the literature and one of the authors himself do not support this statement" is unfounded. While we acknowledge the author's citation of citalopram in treating anorexia nervosa during the acute phase, in both the open trial 3 and the doubleblind, placebo-controlled trial 4 of fluoxetine published by our group, fluoxetine was administered only after acute weight restoration. Therefore, these studies did not assess fluoxetine as a treatment during the ill state when individuals were less than 85% of their ideal body weight. In a recent study by our group, we also reported that administration of nutritional supplements did not increase the efficacy of fluoxetine in underweight individuals with anorexia nervosa. Moreover, in the articles cited by the author of the letter, Kim 6 argued that fluoxetine was not effective as a primary or acute therapy, and although Gwirtsman et al. 7 reported an improvement in depressive symptoms, their study consisted of only 6 subjects with no control group. Taken together, these studies suggest that fluoxetine is effective in preventing relapse only when administered after weight restoration, and not during the acute, underweight phase of the illness.
In response to the author's criticism of our small sample size (N = 17), our original report acknowledged that "these findings must be considered with extreme caution." Moreover, we recognize the author's argument that "anorexia nervosa is a chronic disease that requires long-term treatment" beyond the 6-week period of the study. Nevertheless, this study was designed as an open trial to obtain preliminary data to assess the efficacy of olanzapine in the treatment of anorexia nervosa and to determine the need for a double-blind, placebo-controlled trial. Therefore, the relatively small sample size and short duration of treatment are appropriate. Overall, our results support the need for a controlled study of olanzapine in the acute treatment of anorexia nervosa.
Injection Site Pain With Long-Acting Risperidone
Sir: In a recent report in the Journal, 1 only 1 of 141 patients in a 12-week multicenter trial of injectable long-acting risperidone complained of pain at the site of injection, which was mild. Pain at the injection site has been noted to be a problem with first-generation antipsychotics. 2, 3 The authors speculated that the water-based formulation of risperidone might account for the low frequency of injection site pain. In a previous study, 4 patient ratings of pain on a visual analogue scale after injections of long-acting risperidone were similar to ratings of pain after injections of placebo after the first and sixth injections. Pain after the sixth injection was rated by the investigators as present in 16% to 20% of cases in the 3 dose groups. In another study, 5 injection site pain was found in 32% of patients after the first injection and 20% after the 25th injection. Patients rated the pain as mild, with a median rating of 10 on a 100-mm visual analogue scale after the first injection and 5 after the 25th injection.
In clinical practice as well, pain at the injection site is common. In our experience, 4 of 11 patients who received longacting risperidone in the last 6 months at one of our facilities complained of pain at the injection site. The first injection caused the pain in 2 cases, and in 2 other cases it was caused by subsequent injections. None of these 4 patients refused longacting risperidone, but 1 of them needed encouragement to continue it. Complaints of injection site pain are also reported by a number of prescribers who subscribe to a popular psychopharmacology list serve (list can be accessed by contacting Ivan Goldberg at psydoc@psycom.net).
Risperidone is the only second-generation antipsychotic currently available as a long-acting preparation. This preparation is generally well tolerated and effective and may be less likely than oral risperidone to cause tardive dyskinesia. 6 One of the main reasons for using it is to try to improve compliance. Pain at the injection site is known to be related to compliance with long-acting antipsychotics both in clinical experience and in at least one clinical study 3 ; hence, it is important be aware of this potential side effect and make all attempts to minimize it.
First, the possibility of pain at the injection site should be discussed with the patient in advance. In particular, the patient should be told that the pain is likely to diminish with subsequent injections. Second, the needle used for risperidone injections is 20 gauge (relatively thick). Also, it is about 2 inches long, which makes it probable that the needle can hit the bone in thin individuals, causing pain. While it is important to inject the drug deep intramuscularly, in patients with minimal fat and low muscle mass, the needle should not be injected so deep as to hit the bone. Third, when cold fluid is injected, it can cause cryogenic pain at the injection site. Therefore, the manufacturer's recommendation that the drug should be allowed to come to room temperature before being injected should be scrupulously followed. 7 Fourth, the recommendation to use the buttocks alternately should be followed. 7 Last, administration of an analgesic shortly prior to or at the time of the injection should be strongly considered for cases with persistent pain.
Dr. Lindenmayer and Colleagues Reply
Sir: We thank Drs. Pinninti and Mago for making the important point that pain at the injection site might hamper compliance with long-acting antipsychotics. Although they report that pain at the injection site after administration of long-acting risperidone is common in their patients, this observation does not match the reports of pain assessments in published trials or in our clinical experience.
In the assessment of the impact of repeated injections with long-acting risperidone reported by Kane et al., 1 investigators rated pain at the injection site immediately after the sixth injection as absent in 90% of patients in the placebo group and absent in 80%, 81%, and 84% of patients in the 25-, 50-, and 75-mg risperidone groups, respectively. In the same study, mean patient pain ratings were low at all assessments, with comparable scores among patients receiving placebo and long-acting risperidone. Mean ± SD visual analogue scale (VAS) scores were higher at the first injection compared with the final injection: placebo, 15.6 ± 20.7 (first), 12.5 ± 18.3 (final); 25 mg, 11.8 ± 14.4 (first), 10.0 ± 12.4 (final); 50 mg, 16.3 ± 21.9 (first) 13.6 ± 21.7 (final); and 75 mg, 16.0 ± 17.9 (first), 9.6 ± 16.0 (final, p < .01).
Mean patient VAS ratings were also low at all assessments in the 50-week study reported by Fleischhacker et al. 2 In neither of the studies did patients stop treatment because of injection site pain. According to a recent survey at our own 340-bed inpatient and 450-outpatient psychiatric center, there are currently 87 patients treated with long-acting risperidone. Of these patients, 2 have reported to their psychiatrist any experience of pain at the injection site, and none have refused treatment because of pain experiences.
In conclusion, few patients complain of injection site pain with long-acting risperidone; furthermore, as the authors suggest, reports of injection site pain do not have an impact on the willingness of the patients to continue medication. The authors make a number of very useful recommendations, most of which are currently included in the package insert of the medication. 3 An alternative to their recommendation for the administration of an analgesic prior to or at the time of injection in cases of persistent pain is to choose a different medication administration route. 
Do Antihypertensives Make Tranylcypromine Safer? Three Case Reports
Sir: Monoamine oxidase inhibitors (MAOIs) have never been widely prescribed because of the risk of hypertension when combined with tyramine-containing foods or sympathomimetic amine drugs. 1 Hypertensive reactions have also been reported, albeit less frequently, in patients who adhere to MAOI dietary restrictions. While some of these so-called spontaneous hypertensive reactions have been reported to occur shortly after MAOI ingestion, others appear unrelated to the time of drug intake.
We report on 3 physically healthy treatment-refractory depressed patients taking the MAOI tranylcypromine who had hypertensive symptoms shortly after medication intake that were independent of dietary violations. Each patient's blood pressure was systematically observed (1) within 1 week of hypertensive symptoms before and 30 and 60 minutes after tranylcypromine ingestion and (2) after concomitant treatment with the calcium channel blocker amlodipine before and 30 and 60 minutes after tranylcypromine ingestion. The use of a calcium channel blocker to treat MAOI-induced hypertensive crises has been suggested previously. A total of 5 patients in our clinic have been treated with tranylcypromine since we began prescribing amlodipine for associated increases in blood pressure. One patient exhibited no hypertensive symptoms during treatment, and another patient, upon beginning tranylcypromine treatment, was already being treated with the antihypertensive enalapril. These 2 patients, therefore, did not receive amlodipine. The remaining 3 patients, as reported above, experienced spontaneous hypertensive symptoms shortly after taking tranylcypromine. In each case, prior to treatment with amlodipine, the patient's blood pressure significantly increased 30 to 60 minutes following ingestion of tranylcypromine, with spontaneous remission 30 to 60 minutes later. Each patient denied dietary indiscretion. Whether the rise in blood pressure after MAOI intake explains "spontaneous" hypertensive crises or represents another phenomenon is unclear. It would be worthwhile to report the timing of the last dose of drug and the timing of "spontaneous" hypertensive crises. If hypertension occurs shortly after drug ingestion, it should not be considered spontaneous.
In the 3 patients who experienced hypertensive symptoms, the rise in blood pressure following MAOI intake was prevented when tranylcypromine was combined with the calcium channel blocker amlodipine. There were no patients who did not benefit from the addition of amlodipine. The possibility of medication-induced hypertensive crisis needs to be monitored in any patient taking tranylcypromine. Whether this concern applies to other MAOIs is unknown. Our data do not clarify the role of maintenance calcium channel blocker therapy in preventing a hypertensive reaction to accidental ingestion of tyramine-containing foods. 2004 was in December 2003. The HAM-D was not performed at that time, but her mood was noted as "upbeat-smiling and talkative," and the absence of delusions or hallucinations was noted. She had no prior history of psychotic symptoms with her major depressive disorder, and she had never experienced especially vivid or intense dreaming or difficulty distinguishing dreams from reality.
Her primary care doctor started her on treatment with memantine after it became available in the United States in January 2004. She initiated therapy at 5 mg twice each day from January 13, 2004, to February 13, 2004 . Her dose was then increased to 10 mg twice each day. She had no other medication or medical changes at that time.
Six weeks after being placed on treatment with the higher dose, Ms. A reported that she had been feeling more "confused" during the day and had been having intense, vivid dreams and nightmares. She had trouble distinguishing the dreams from reality. In July 2004, she became convinced that an event she had dreamed, the illness of a family member, was real. She called local area hospitals to find her relative. At this point, her primary care doctor discontinued memantine treatment, and the patient's confusion and intense dreaming resolved quickly. This symptom has not recurred since the discontinuation of memantine.
Vivid and intense dreams or nightmares can be a symptom of psychosis. This symptom can be an adverse effect of dopaminergic therapy for Parkinson's disease, 7, 8 a symptom of schizophrenia, 9 and an adverse effect of other medications that act on the central nervous system. 10, 11 Case studies of psychotic symptoms with memantine treatment of Parkinson's disease have been reported, 12 but not, to our knowledge, with memantine use in Alzheimer's disease. In this case report, we describe a woman with mild Alzheimer's disease who experienced vivid, intense dreams and nightmares and difficulty distinguishing dreams from reality after being started on memantine treatment. The dreams stopped after discontinuation of memantine. This patient suffers from major depressive disorder, which can also be a cause of psychotic symptoms. However, to the best of our knowledge, her depressive disorder was stably in partial remission and has never been associated with psychotic symptoms.
Memantine shares a mechanism with medications known to cause psychotic adverse effects. However, memantine shows strong voltage dependency and rapid blocking/unblocking kinetics, which may explain the low rates of psychiatric adverse effects reported with its use in controlled clinical trials. 13 Of note, the reported potential psychiatric adverse effects in the package insert 1 include confusion, hallucinations, agitation, insomnia, depression, anxiety, and somnolence. Subtle psychotic adverse effects may not have been specifically detected as a potential adverse effect. In a recent study of patients with moderate-to-severe Alzheimer's disease, "agitation" was listed as the most common reason for discontinuation of memantine. 14 Psychotic adverse effects such as those experienced by our patient may contribute to agitation, and these symptoms can be difficult to detect, especially in a moderately to severely demented population. We recommend that clinicians prescribing memantine evaluate patients carefully for subtle psychotic symptoms. 
